此次签约标志着乐城医疗核心能级再升级。中山大学中山眼科中心整体学科水平排行亚洲第一，吉 林大学中日联谊医院综合实力位居全国前列，这两家医疗"国家队"的入驻，将为乐城建设国际医疗中心 注入强劲动能。 海南日报讯 (海南日报全媒体记者 王子豪 通讯员 袁昌佑)海南日报全媒体记者从乐城管理局获 悉，2025年12月30日，乐城管理局分别与省卫生健康委、中山大学中山眼科中心，吉林大学中日联谊医 院就合作共建中山大学中山眼科中心海南国际眼科医院、吉林大学中日联谊医院乐城医院签署合作协 议。 根据协议，各方将整合乐城先行区特许药械、生物医学新技术、国际医疗合作等政策红利与签约医 院优质医疗资源，为国内外患者提供高标准的诊疗服务，打造乐城先行区特色医疗标杆项目，并在科研 创新、人才培养等领域开展多元合作，实现"立足海南、服务全国、贡献全球"的愿景。 ...

11月29日上午，随着梁山县人民医院党委书记宋培忠与首都医科大学附属北京安贞医院心内科张锋教授 共同揭下红色绸缎，"急性心肌梗塞临床研究合作医院"牌匾在梁山县人民医院办公楼第一会议室正式亮 相。北京安贞医院心内科张锋、罗伟两位教授受邀出席仪式，此次合作的成功落地，标志着国内心血管 领域顶尖资源与县域医疗龙头完成深度绑定，京梁医疗协作在急危重症救治领域迈出关键一步。 梁山县人民医院党委委员、副院长杨作祥在致辞中坦言，尽管医院在胸痛救治方面积累了一定经验，但 在复杂病例处理和科研转化上仍有短板。"与安贞医院合作，为我们打开了通往顶尖心血管技术的大 门。"他表示，医院将全力做好保障工作，建强研究阵地、规范诊疗流程、组建专业团队，虚心学习借 鉴安贞医院的先进经验，切实将合作成果转化为服务实效，"让每位患者得到及时、精准、高效的救 治"。 北京安贞医院心内科张锋教授在致辞中表示："医疗合作之路，行则将至；健康守护之责，做则必 成。"他与罗伟教授一致表示，作为国家心血管疾病临床医学研究中心，安贞医院将秉持"优势互补、资 源共享、协同创新"的原则，以最大诚意、最优资源、最实举措推动合作落地见效，让梁山群众在家门 口就能享受 ...

Group 1 - Enjie Co., Ltd. is planning to acquire 100% equity of Zhongke Hualian and will suspend trading from December 1, 2025 [3] - ST Tianrui's controlling shareholder is planning a change in company control, leading to a trading suspension from December 1, 2025, expected to last no more than two trading days [4] - Jiarong Technology intends to raise no more than 1 billion yuan through a private placement and acquire 100% of Hangzhou Lanran [5] Group 2 - Baillie Gifford's subsidiary received a milestone payment of $250 million related to a collaboration agreement with Bristol-Myers Squibb [6] - Jiangxi Copper is planning to acquire shares of the overseas listed company SolGold Plc, with a non-binding cash offer of 26 pence per share [7][8] - China Shenhua's subsidiary successfully completed a 168-hour trial run of the No. 3 unit of the Beihai Phase II project, which is a key energy development project in Guangxi [9] Group 3 - Huayang Co., Ltd. has launched a high-performance carbon fiber project with an annual production capacity of 200 tons [11] - Dameng Data announced the release of its general manager from detention by the local supervisory committee [12] Group 4 - Zhongwei Company plans to reduce its stake by up to 1% through a block trade [13] - Yulide's board members plan to reduce their holdings by no more than 0.0313% of the company's total shares [14] - Saint Noble Bio's executives plan to reduce their holdings by no more than 0.024% of the company's total shares [15] Group 5 - Aoride plans to sign a comprehensive technical service agreement with a total amount of approximately 635 million yuan [16]

Core Viewpoint - The successful completion of a complex surgical procedure by the Chinese medical team in South Sudan highlights the professionalism and humanitarian commitment of China's foreign aid medical teams [1][2] Group 1: Surgical Procedure Details - The Chinese medical team performed a high-difficulty surgery, specifically an "ovarian endometriosis cyst removal and pelvic adhesion release," on a 30-year-old female patient in Juba Teaching Hospital [1] - The surgery was conducted under challenging conditions, including a lack of laparoscopic and complex anesthesia monitoring equipment, leading the team to opt for a spinal anesthesia approach [1] - The patient presented with severe pelvic adhesions and a significant mass, with the surgical team successfully navigating the complexities of the procedure, including controlling intraoperative bleeding and ensuring complete cyst removal [1] Group 2: Team Collaboration and Local Impact - The surgical team consisted of gynecologist Guan Chunfeng, anesthetist Wang Jiayou, and nurse Ma Biao, who worked in close collaboration with local medical staff, receiving high praise for their professionalism and dedication [2] - The success of the surgery not only alleviated the patient's suffering but also served as a testament to the medical cooperation between China and South Sudan, reinforcing China's commitment to building a global health community [2] - Guan emphasized that conducting complex surgeries in resource-limited settings is a significant test of medical skills and a deepening of commitment to their mission, reflecting the unwavering dedication of Chinese foreign aid medical personnel [2]

Core Points - The establishment of the "Gynecological Oncology Team Studio" by Fudan University Affiliated Obstetrics and Gynecology Hospital marks a significant step in enhancing women's health services in Lianyungang City [1][3][5] - The collaboration aims to improve the diagnosis and treatment capabilities for complex gynecological conditions in the region, benefiting local residents with access to top-tier medical resources [7][9] Group 1: Event Overview - The unveiling ceremony took place at Lianyungang Maternal and Child Health Hospital, attended by key officials including the Vice Mayor of Lianyungang and the hospital's leadership [1][3] - The initiative is part of Lianyungang's strategy to deepen cooperation with leading medical institutions and enhance regional healthcare capabilities [3][5] Group 2: Institutional Goals - Lianyungang Maternal and Child Health Hospital aims to strengthen its specialized capabilities in gynecology, achieving recognition as a provincial clinical key specialty unit [5] - The hospital has implemented AI technology for comprehensive screening of women's cancers and has been designated as a national monitoring site for cancer projects [5] Group 3: Expert Involvement - The expert studio will focus on gynecological tumors and complex cases, with top specialists providing consultations and technical guidance at the local hospital [7] - The initiative is expected to significantly elevate the local gynecological diagnosis and treatment capabilities, ensuring that residents can access high-quality medical services nearby [7][9] Group 4: Educational Initiatives - Following the unveiling, a specialized lecture was conducted by the hospital's president on the exploration and practice of clinical specialty capacity building in obstetrics and gynecology [13]

Group 1 - Humana Inc. has partnered with DrFirst to launch a program aimed at closing care gaps for patients with chronic conditions, focusing initially on increasing statin therapy usage among eligible patients [1][11] - The initiative leverages DrFirst's prescription orchestration platform to directly engage prescribers, allowing Humana to send statin therapy recommendations for high-risk patients to providers [2][11] - DrFirst's platform enhances clinical collaboration by ensuring seamless interoperability among providers, pharmacies, and payers, facilitating quick sharing of critical patient information [3][4] Group 2 - The partnership reflects Humana's commitment to strengthening ties with DrFirst, which has been providing advanced medication management solutions for nearly three decades [4][5] - The use of DrFirst's platform is expected to improve health outcomes, potentially increasing customer retention and attracting new members to Humana's healthcare plans [6][11] - As of June 30, 2025, Humana's total medical membership reached 14.8 million, with premiums increasing by 8.6% year over year in the first half of 2025 [6]